復旦張江(01349.HK):鹽酸氨酮戊酸顆粒劑用於膀胱癌手術可視化驗證性臨牀試驗完成首例受試者入組
格隆匯3月13日丨復旦張江(01349.HK)發佈公告,集團研發的鹽酸氨酮戊酸顆粒劑(“該藥物”)用於非肌層浸潤性膀胱癌手術切除輔助的驗證性臨牀研究(“該研究”)於近日成功完成首例受試者入組。
膀胱癌是一種複發率較高的惡性腫瘤。根據腫瘤是否浸潤到膀胱肌層可以分爲非肌層浸潤性膀胱癌(“NMIBC”)和肌層浸潤性膀胱癌(MIBC)。據公開資料顯示, NMIBC 約佔膀胱癌的75%。經尿道膀胱癌切除術(“TURBT”)是目前治療 NMIBC 的首選外科治療方式,目標是完全切除腫瘤。臨牀治療中,TURBT 術後的腫瘤殘餘是 NMIBC 復發的重要原因之一。因此,公司擬開發該項術中熒光指引技術,提高 TURBT術中 NMIBC的檢出率,以幫助醫師更完全地切除腫瘤組織,從而降低患者複發率。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.